GET THE APP

Anticancer Drug Development | Open Access Journals
Journal of Oncology Medicine & Practice

Journal of Oncology Medicine & Practice

ISSN: 2576-3857

Open Access

Anticancer Drug Development

MicroRNAs and other non-coding RNAs as focuses for anticancer medication improvement. With the main malignancy focused on microRNA sedate, MRX34, a liposome-based miR-34 copy, entering stage I clinical preliminary in patients with cutting edge hepatocellular carcinoma in April 2013, miRNA therapeutics are drawing in uncommon consideration from both scholarly world and biotechnology organizations. Despite the fact that to date the most considered non-coding RNAs (ncRNAs) are miRNAs, the significance of long non-coding RNAs (lncRNAs) is progressively being recognized.Non-coding RNAs (ncRNAs) include different classes of RNA transcripts that are not interpreted into proteins, however have been appeared to control the interpretation, dependability or interpretation of protein-coding qualities in the mammalian genome 1, 2

High Impact List of Articles
Conference Proceedings

Relevant Topics in Medical Sciences

arrow_upward arrow_upward